PMID: 15218971Jun 29, 2004Paper

EBV-positive Burkitt lymphoma as a late-onset posttransplantion lymphoproliferative disorder after allogeneic stem cell transplantation

International Journal of Hematology
Naohiro SekiguchiK Tobinai

Abstract

Posttransplantation lymphoproliferative disorder (PTLD) is one of the well-recognized complications after allogeneic stem cell transplantation (SCT). It generally occurs early after SCT, and only a few reports of late-onset cases are available. We report a 58-year-old male patient who developed lymphoma 4 years after allogeneic SCT for chronic myeloid leukemia. The presence of c-myc translocation and Epstein-Barr virus-encoded RNA in the lymphoma cells, without rearrangement of the 3'-bcr region, confirmed the histopathologic diagnosis of Burkitt lymphoma. DNA chimerism analysis revealed that the lymphoma cells were of donor origin. The patient achieved complete response with intensive chemotherapy. To our knowledge, this is the first report of Burkitt lymphoma as a PTLD occurring after allogeneic SCT.

References

Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I MagrathI D Horak
Mar 15, 2000·The American Journal of Surgical Pathology·B P NelsonS H Swerdlow
Dec 2, 2000·Nature Medicine·B KwakF Mach
Jun 14, 2001·The American Journal of Medicine·L M Bjerre, J LeLorier
May 27, 2003·The American Journal of Surgical Pathology·Jerald Z GongPatrick J Buckley

❮ Previous
Next ❯

Citations

Mar 18, 2006·Internal Medicine·Shosaku NomuraEiji Kadota
May 3, 2011·Néphrologie & thérapeutique·Sophie CaillardBruno Moulin
Apr 1, 2006·Transplant International : Official Journal of the European Society for Organ Transplantation·Jakub SvobodaDonald E Tsai
Feb 2, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akiko YamadaAkihiko Gotoh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved